Radiofrequency ablation of the centromedian thalamic nucleus in the treatment of drug-resistant epilepsy

Epilepsy Behav. 2021 Jan;114(Pt A):107560. doi: 10.1016/j.yebeh.2020.107560. Epub 2020 Nov 24.

Abstract

Objective: To determine the usefulness and efficacy of radiofrequency ablations (RFA) of the Centromedian thalamic nucleus (CMN) to control primarily generalized or multifocal seizures in refractory epilepsy.

Methods: Six patients with clinical diagnosis of multifocal or primarily generalized drug-resistant epilepsy were included. Bilateral RFA of the CMN was performed through a monopolar 1.8 mm. tip electrode with a temperature of 80 °C during 90 seconds. Patients were followed in every 3 months visit for 20 to 36 months and kept a monthly seizure count calendar. We also compared maximal paroxysmal electroencephalogram (EEG) activity and neuropsychological evaluation pre and 6 months postoperatively.

Results: A significant reduction in the number of generalized seizures was observed in all subjects in the range of 79-98%, starting the first post-operative month. Although focal aware seizures remained unchanged throughout follow-up, there was an important reduction on paroxysmal activity between the pre and postoperative EEG. No major changes on cognitive status were detected. There was post-operative dysphagia and odynophagia lasting one week and there was no mortality in this group of patients.

Conclusion: Preliminary results of CMN RFA suggest safety and a trend toward reduction of some seizure types, it may reduce the seizure frequency like other palliative procedures since the first post-operative month, but a larger, controlled study would be needed to establish the value of this therapy.

Keywords: Centromedian thalamic nucleus; Generalized epilepsy; Multifocal epilepsy; Radiofrequency ablation; Refractory epilepsy.

MeSH terms

  • Drug Resistant Epilepsy* / surgery
  • Electroencephalography
  • Humans
  • Intralaminar Thalamic Nuclei*
  • Pharmaceutical Preparations*
  • Radiofrequency Ablation*

Substances

  • Pharmaceutical Preparations